Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review.

Abstract

Agents that inhibit programmed cell death (IPD-1) in T lymphocytes are indicated for patients with advanced cancer. However, some individuals may develop endocrinological conditions, such as diabetes, thyroid dysfunction, and lipodystrophy, after treatment. This systematic review and case report of IPD-1 lipodystrophies describes a patient who received nivolumab treatment for advanced clear cell renal carcinoma and subsequently developed diabetes as well as facial and body lipodystrophy. The patient complained of social distress due to her facial appearance. We treated the facial lipodystrophy with autologous fat grafting, which proved to be effective for more than three years. This study showed the efficacy of IPD-1 lipodystrophy treatment with long-term follow-up.